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Abstract
Background: Gallstone disease is common with a high prevalence in developed nations and is
expected to rise as the obesity and metabolic syndrome epidemic worsens. The associated
relationship between gallstone and biliary tract disease is complex. The most effective treatment
approach for patients with concomitant gallstones and bile duct stones is controversial. Multiple
different combinations of one-step and two-step endoscopic and/or surgical techniques exist.
Advancements in laparoscopic and endoscopic methods have paved the way for a minimally
invasive approach to managing cholecystocholedocholithiasis (CCL).
Methods: A literature review was conducted via systematic search of Google Scholar and
PubMed to evaluate articles comparing various interventions and associated complications and
outcomes between them.
Discussion: There are advantages and disadvantages amongst of each treatment strategy without
a clear consensus as to which procedure is superior. Although a two-stage sequential approach is
most often used in real-world clinical practice, the literature reports many favorable outcomes for
a single-step procedure in terms of fewer complications, better bile duct clearance, and shorter
hospital stay. Preferential treatment for a one-step protocol is also attributed to the economic
pressure to limit costs and resources being used.
Conclusion: Evidence from the literature continues to support the use of endoscopic retrograde
cholangiopancreatography (ERCP) and laparoscopic cholecystectomy (LC) as the mainstay
treatment in patients with concurrent gallbladder and bile duct calculi. Currently, gold standard
treatment is determined at the specific healthcare practice led by local professional expertise of a
multidisciplinary team, endoscopist or surgeon preferences, patient risk, and available resources.

Management of Gallstones and Bile Duct Stones 4
Introduction
The relationship between gallstone and biliary tract disease is continually evolving and
requires further investigation to fully describe the interplay between pathological processes. The
most effective treatment method for patients with concurrent gallbladder and bile duct stones is
controversial and debate remains regarding how to treat both diseases simultaneously.1 In
Western nations, particularly the United States, gallstones are common with about 15%
prevalence in Americans and upwards of 700,000 cholecystectomies are performed annually.2 It
is a leading cause for hospital admissions and an increase of gallstone frequency is expected as
the rising obesity and metabolic syndrome epidemic continues to escalate.3 Gallstone-related
complications and symptoms is an estimated $6.5 billion yearly which surpasses the combined
healthcare costs for chronic liver disease and pancreatic disorders, making it one of the costliest
digestive conditions.4
Gallstone disease is linked with an overall increase in cardiovascular and cancer
mortality.3 About 98% of biliary tract disorders are related to gallstones, and approximately 10%
of patients with symptomatic cholelithiasis will also develop choledocholithiasis.2 Depending on
patient age, the rate of choledocholithiasis in those presenting with acute cholecystitis is between
15-33%.5 The association of both conditions can cause multiple severe complications changing
the choice of best approach for treating a benign issue into a possible life-threatening problem.
Patients with symptomatic gallstones are at high risk for biliary complications.6 Cholelithiasis
being the presence of gallstones in the gallbladder, followed by cholecystitis, an acute
inflammation and infection of the gallbladder. The presence of stones in the common bile duct
(CBD) is choledocholithiasis. Collectively this disease state is referred to as
‘cholecystocholedocholithiasis’ or ‘CCL’ throughout the literature.21,22
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There is a severity spectrum in terms of clinical manifestations ranging from
asymptomatic stones to repeated biliary pain attacks, all the way up to severe or life-threatening
complications including hepatic abscesses, acute biliary pancreatitis, cholangitis, or obstructive
jaundice.6 Patients who present with mild, non-specific symptoms may be misdiagnosed if their
symptoms are attributed to other illnesses and may receive unnecessary testing, imaging, and
treatments. Recognizing the specific signs/symptoms, physical exam findings, and risk factors
for gallbladder and biliary disease is imperative to properly image and diagnose so that patients
receive appropriate treatment.7 A range of therapeutic endoscopic and surgical options are
available, but there is uncertainty surrounding the safest and most effective combination of
sequential treatment. Current data fails to provide clear evidence as to whether a single-step
procedure or multi-stage approach is superior.6 Additionally, there is deliberation surrounding
the timing of cholecystectomy as whether it should be performed prior to bile duct stone
clearance or afterwards.7
The purpose of this paper is to identify the ‘gold standard’ for detection and treatment of
CBD stones in patients undergoing laparoscopic cholecystectomy (LC). Endoscopic procedures
are characteristically invasive and potential complications are not always preventable even when
performed by skilled physicians.8 Rigorous randomized clinical trials are required to assess and
compare various treatment technique outcomes to determine which method will yield higher
success rates and fewer complications. The most common long-term complication after gallstone
surgery is recurrent bile duct stones and there are no effective therapies for prevention.9
Surgically removing the gallbladder does not entirely eliminate the risk of CBD stones because
they can recur or residual stones may remain. CBD stone recurrence happens in a considerable
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number of post-cholecystectomy cases, necessitating further inquiry into the
prevalence/incidence and risk factors, especially given lack of data on the issue.10
This paper seeks to clarify and organize the most up-to-date data and agreement on best
endoscopic and surgical practices in the general patient population for concomitant gallstones
and bile duct stones. This comparative treatment literature review sought to determine which
approach is superior in the management of CCL. Differences in procedural techniques,
outcomes, and complications were outlined to try and determine the most effective intervention
for patients with concurrent cholelithiasis and choledocholithiasis. First this paper will outline
the pathogenesis of cholecystocholedocholithiasis, followed by risk factors for stone
development, then clinical manifestations of each disease state, and various preoperative
predictive factors used to assess bile duct stone likelihood. The investigation and diagnosis in the
workup of both gallstone and biliary disease with imaging modalities is discussed with a
subsequent presentation of the literature comparing all of the treatment approaches. Lastly, the
role of cholecystectomy before or after bile duct clearance is addressed as well as risk factors for
post-operative stone recurrence. This paper will conclude with a discussion of the treatment
interventions and their success rates, implications for future research, and a final conclusion to
address the question of what the most effective management is for patients with concomitant
gallstones and bile duct stones.
Background: Literature Review
Pathogenesis of Cholecystocholedocholithiasis
Before delving into the etiology and development of disease, it’s important to have an
understanding of basic anatomy of the gallbladder and neighboring biliary tree. The gallbladder
is an intraperitoneal organ that sits between the inferior aspect of the right and quadrate lobes of
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the liver. Its primary function is to concentrate and store bile produced by liver hepatocytes.
Stored bile is released in response to the hormone cholecystokinin and flows freely in and out of
the gallbladder via the cystic duct. A mucosal fold called ‘Hartmann’s Pouch’ is contained
within the neck and is a common site for gallstones to become stuck triggering cholestasis. The
neck of the gallbladder tapers to become continuous with the cystic duct, leading into the biliary
tree. As the cystic duct descends down it is joined by the common hepatic duct to eventually
form the common bile duct (CBD). The CBD slopes downward and passes behind the first part
of the small intestine and pancreas head where it joins the pancreatic duct forming what is known
at the ampulla of Vater. This hepatopancreatic ampulla empties into the duodenum through the
main duodenal papilla that is regulated by a muscular valve called the sphincter of Oddi.
Altogether, the biliary tree is a series of gastrointestinal ducts that drain the liver, gallbladder,
and pancreas with drainage routes emptying into bowel.11
The processes leading to stone formation can occur within the gallbladder, CBD,
extrahepatic or intrahepatic ducts.12 A complex interplay between environmental factors and
genes plays a role in the creation of stones, specifically diet-gene interactions.3 Gallstones are
classified according to their predominant chemical composition as cholesterol or pigment stones
(CMDT 2020). The overwhelming majority of gallstones in developed countries consist of
cholesterol (more than 80%) while the rest are pigment or mixed. Cholesterol calculi are created
due to biliary stasis, supersaturation of cholesterol, and excess mucus secretion of the
gallbladder. An imbalance of cholesterol, bile salts, and lecithin which make up bile are
responsible for the excess cholesterol microcrystal production that leads to aggregation of hard
crystal-like particles. Individuals who develop black pigment stones have elevated levels of
conjugated bilirubin resulting from chronic or recurrent hemolysis or higher levels of
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unconjugated bilirubin related to alcohol abuse or liver cirrhosis. Brown pigment or mixed stones
composed of calcium bilirubinate arise secondary to bacterial breakdown of bile and
accompanying biliary stasis. When brown pigment stones form de novo in the CBD, it is
considered primary choledocholithiasis and typically associated with bacterial infection or biliary
parasites, dilated bile ducts, duodenal diverticulum, or ampulla of Vater stenosis. Chronic stasis
in the biliary tree is a major component to the pathogenesis of primary CBD stone formation.12
Migration of cholesterol stones from the gallbladder out of the cystic duct into the biliary
tree are termed secondary CBD stones.12 Once gallstones make their way into the CBD, they
may remain dormant for many years, pass spontaneously into bowel, or cause acute issues
related to symptomatic infection and/or obstruction.12,13 After LC the median time until the first
appearance of symptomatic retained CBD stones is 4 years. When patients develop symptomatic
choledocholithiasis, nearly half of them end up with a noteworthy infection or obstruction.12
Choledocholithiasis is a hepatobiliary disease with underlying pathology of impaired cholesterol,
bilirubin, and bile acid metabolism, that sometimes may be chronic in nature.14 Secondary
choledocholithiasis is a complication of cholelithiasis and in industrialized nations represents the
vast majority of stones found in the biliary tree that form in association with infection or
inflammation stemming from biliary strictures and malignancies.3 The development of
cholecystitis happens when there is gallbladder outlet obstruction from a stone in the neck of the
cystic duct persisting for greater than 12 hours. This blockage leads to increased intraluminal
pressure and subsequent influx of fluid into the surrounding gallbladder lumen. The trapped bile
becomes concentrated and causes irritation and pressure build-up in the gallbladder.
Inflammatory processes and bile stasis can lead to secondary bacterial infection most often from
Escherichia coli, Klebsiella, Enterobacter, and other gram-negative enteric organisms.12
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Risk Factors for Stone Formation and Gallstone Disease
There are various modifiable and non-modifiable risk factors that put individuals at
higher risk for developing cholesterol and pigment gallstones over the course of a lifetime.
Ethnic background, genetics and family history, advancing age, female sex and pregnancy are all
features that cannot be changed.3 Certain ethnic groups are more predisposed to developing
gallstones and rates are higher in Mexican Americans than in non-Hispanic whites and African
Americans. The high prevalence of gallstones in American Indians in both South and North
America is almost 70% as compared to 10-15% in the adult Caucasian population.12 Native
Americans high rate of cholesterol cholelithiasis likely results from a genetic predisposition for
LITH genes that promote efficient calorie utilization and adipose storage. In East Asian
populations brown pigment stones are the main type of primary ductal stone primarily attributed
to parasitic infiltration. This predominant stone type in developing Asian countries has been
shifting to more cholesterol composition as there is more ingestion of a Westernized diet and
reduced incidence of chronic biliary infections.3
Genetic predisposition and family history both significantly contribute to gallstone
development with an almost 5 times increased risk in relatives. Even higher rates are found in
monozygotic twin familial studies. Although several identified genes have been implicated in
gallstone disease susceptibility, multiple different genes are more likely contribute to
cholelithiasis. Advancing age is highly correlated with stone formation due to increased
cholesterol secretion resulting in frequent symptoms and ultimately more cholecystectomy
surgeries. Women are twice as likely to develop gallstones as compared to men, especially when
they’re fertile due to estrogen and progesterone. Endogenous female sex hormones impair
gallbladder function and emptying as well as increase cholesterol secretion. Pregnancy is a well-
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known physiological state leading to gallstone formation and biliary sludge that resolves during
the post-partum period.3 Use of hormonal contraceptives is a significant modifiable risk factor
that makes women 3 times more likely to form gallstones.4
Underlying chronic diseases with a strong genetic inheritance including sickle cell
anemia, cystic fibrosis, and Crohn’s disease (or ileocolic resection) are all correlated to stone
formation. Sickle cell disease specifically predisposes individuals to form black pigment stones
because of chronic hemolysis and excessive bilirubin excretion. Some changeable factors
involved in stone pathogenesis are obesity, metabolic syndrome, dyslipidemia, diabetes mellitus
type II, physical inactivity, rapid weight loss (especially after bariatric surgery), high glycemic
diet and prolonged fasting, total parental nutrition, alcoholic liver cirrhosis, and certain drugs
(octreotide, ceftriaxone, thiazide diuretics).3
Clinical Manifestations of Cholelithiasis vs. Cholecystitis vs. Choledocholithiasis
Silent gallstones isolated to the gallbladder without inflammation or symptoms are most
common and found incidentally on imaging.12 Individuals who develop asymptomatic
cholelithiasis with low risk for biliary complications are not considered good candidates for
elective cholecystectomy and instead receive expectant management. It is estimated that about
20% of these asymptomatic patients become symptomatic after 10 years.4 If patients develop
biliary ‘colic’ with episodic abrupt onset abdominal pain, they may require surgery, especially if
complications occur. It is important to differentiate true biliary pain from nonspecific abdominal
pain related to dyspepsia, gastroesophageal reflux disease, or irritable bowel syndrome.
Gallstone-related pain has very specific characteristics and associated symptoms that patients
will experience relief from by having their gallbladder taken out.3
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Elucidating certain patterns seen in patients with symptomatic cholelithiasis or
choledocholithiasis is necessary to prevent overuse of redundant cholecystectomy and to utilize
appropriate imaging to uncover the stone location and size.3 A typical episode of ‘gallbladder
attack’ can be described as rapid-onset and constant pain that peaks between 30-60 minutes and
lasts a few hours before slowly resolving. Most often this severe pain is in the right upper
quadrant (RUQ), but also occurs in the epigastric region or even retrosternal area. These repeated
painful attacks are often precipitated by a large or fatty meal and patients with symptomatic
gallbladder stones may be nauseous and restless at night. If this biliary pain continues more than
a 12-hour period, acute cholecystitis is suspected, particularly in the setting of fever or
tachycardia indicating a systemic inflammatory response. The RUQ or epigastric pain is
continuous and the patient is more likely to be nauseous and vomit due to severe pain. Repeated
painful attacks are often precipitated by a large or fatty meal due to cholecystokinin-induced
gallbladder contraction.12
Radiation of biliary pain to the right shoulder or subscapular area is Boas sign caused by
phrenic nerve irritation and indicates significant gallbladder inflammation. On physical exam the
gallbladder may be enlarged and palpable, and Murphy’s sign can be performed to elicit
inspiratory arrest with palpation over the RUQ anatomical region. Labs are normal in
cholelithiasis but an elevated white blood cell count is the main inflammatory marker (greater
than 15,000) used clinically in cholecystitis. Although the leukocytosis with left shift is the
predominant lab finding, there may also be accompanying increased bilirubin, alkaline
phosphatase (ALP), and liver function tests (LFTs). Distinguishing cholecystitis lab findings
from choledocholithiasis is the hallmark markedly elevated ALP and gamma-glutamyl
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transferase (GGT) due to cholestasis. Both LFT serum markers aminotransferase (AST) and
alanine aminotransferase (ALT) are mildly elevated in patients with CBD stones.12
Primary and secondary choledocholithiasis have the same symptom presentation and
complications. The clinical manifestations of biliary pain in choledocholithiasis cannot usually
be distinguished from gallbladder stone pain. However, the biliary colic is typically more
prolonged because of the presence of the stone blocking the bile duct. When a CBD stone either
slows or blocks the flow of bile from the liver (extrahepatic cholestasis) to the small intestine
there are other differentiating features such as jaundiced skin/sclera, pruritis, dark urine, pale or
clay-colored stool. When impediment of the CBD lasts longer than 12-18 hours, obstructive
jaundice will often fluctuate over a period of time and may eventually dissipate. If the distal
CBD becomes occluded by a stone, this in turn causes similar biliary colic pain in an episodic
repeating manner as gallbladder outlet obstruction. When the CBD obstruction is transient in
nature and resolves, abdominal pain is the main symptom without jaundice or sepsis.12
The identical pain patterns in patients with obstruction of the CBD or gallbladder outlet
makes it difficult to ascertain the stone site of origin without proper imaging to delineate the
specific cause. The frequency, severity, and nature of symptoms reported in the patient history
are vital to establishing the acuity level and clinical picture to determine the most appropriate
and least invasive imaging modality to allow for successful treatment.
Preoperative Predictive Factors to Assess Bile Duct Stone Risk
In approximately 8-12% of all patients who receive cholecystectomy for symptomatic
gallstone disease, CBD stones are also present.15 Because they are often an unexpected finding at
the time of cholecystectomy, being able to accurately predict the potential for concurrent ductal
calculi in patients with symptomatic cholelithiasis is useful.16 Furthermore, having a clean CBD
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before moving on to LC is preferred by most surgeons so being able to rule in or out
choledocholithiasis is imperative.17 Multiple research studies have explored and attempted to
identify various parameters that are highly correlated with the presence of CCL. This is
important because predicting bile duct stones and confirming their presence is not
straightforward, so several predictive methods have been proposed based on clinical, lab, and
imaging factors, but in general all have low diagnostic sensitivity.1 Decisions regarding risk
assessment for suspicion of ductal stones and initial diagnostic evaluation has consequences
relating to under or overtreatment of patients and associated health-related quality of life.13
A negative result of the absence of a concrete scoring system to accurately predict patient
CBD stone risk means that surgeons are inclined to perform an increased amount of negative
ERCPs (endoscopic retrograde cholangiopancreatography) prior to LC, leading to longer hospital
stay, wasted money, and poorer patient outcomes.1 There was a trend early on in the laparoscopic
age for routinely doing precholecystectomy ERCP, but it led to numerous negative retrograde
cholangiograms and a high incidence of post-ERCP pancreatitis (PEP).18 To lower the number of
unnecessary ERCPs, scoring thresholds should be increased which would shift to more reliance
on intraoperative diagnosis.1,19
In the diagnostic work-up process for CBD stones several different identified
biochemical markers may be helpful in being highly suggestive of ductal stones compared to
those with low probability. The serum lab values include bilirubin, transaminases (AST/ALT),
alkaline phosphatase (ALP), GGT, lactatedehydrogenase (LDH), and amylase/lipase. Besides
labs, ultrasonography imaging showing dilatation of the CBD is also theorized to be associated
with the presence of choledocholithiasis, but to date no clinical or laboratory measure can predict
CBD stones with ideal accuracy.6,19 In most clinical scenarios, whether non-emergent or acute,
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bilirubin is the more reliable laboratory test in predicting the presence of bile duct stones. Total
bilirubin greater than 4 mg/dL is a very strong predictor and bilirubin values between 1.8-4
mg/dL is a strong indication of choledocholithiasis. Comparatively, abnormal liver tests are only
moderately predictive of ductal calculi. Aminotransferases may be elevated non-specifically and
therefore not as helpful in the investigation of CCL. Elevated GGT is also a moderate predictor
of bile duct stones. In general, upward trends of GGT and ALP are most specific for evaluating
the presence of cholestasis due to blockage in the CBD. The other biomarkers listed are less
reliable and not utilized consistently in CCL work ups. When looking at the entire clinical
picture of a patient all the other labs may be useful but at large are not used on an individual
basis to make decisions about diagnostic imaging or treatment.12, 19, 20 Further details regarding
the use and application of these different tests will be discussed at the end of this section.
Assessment of operative risk is crucial prior to scheduling any interventions.5 Patients
scheduled to undergo LC, need preoperative risk assessment for CBD stones using imaging and
liver function tests (LFTs).13,18 Raised liver transaminases may be indicative of a ductal stone,
however it’s well-known that their use is limited attributable to their low positive predictive
value, sensitivity, and specificity. Normal liver enzymes have an equitable negative predictive
value whereby only 3% of patients were found to have CBD stones on operative
cholangiography during cholecystectomy.12 Hepatic labs are evaluated for evidence of
cholestasis and ultrasound (US) is performed to note whether or not the CBD is widened, with
greater than 6 mm being the cutoff for being deemed dilated.12,19 The highest predictive power
discovered in most studies was CBD diameter which was shown to be directly correlated with
the likelihood of bile duct stone presence.16
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Individuals with normal LFTs and duct diameter smaller than 6 mm are unlikely to have
choledocholithiasis.12,18 In a retrospective analysis followed by prospective study, aiming to
define pre-operative risks for choledocholithiasis, researchers found that all gallstone disease
patients with CBD diameter less than 6 mm did not have any concomitant CBD stones. On the
contrary, every single cholecystectomy patient with a CBD diameter equal to or greater than 11
mm had confirmed presence of CBD stones. Their data reports that CBD diameter between 7-10
mm corresponded to a 23% rate of concurrent ductal stones.16 The cutoff of 6 mm may miss
stones but in general the relationship between CBD diameter and stone probability is directly
proportional. UpToDate provides a percentage breakdown of CBD stone probability – 0 to 4 mm
CBD diameter: 3.9% ductal stone probability, 4.1 to 6 mm CBD diameter: 9.4% ductal stone
probability, 6.1 to 8 mm CBD diameter: 28% ductal stone probability, greater than 10 mm CBD
diameter: 50% ductal stone probability. As people age, the ductal diameter enlarges, so older
adults may have a normal CBD size relative to their age even if greater than 6 mm.21
The American Society for Gastrointestinal Endoscopy (ASGE) outlined three categories
of patients grouped by low, intermediate, or high risk for choledocholithiasis in their 2010
guidelines. Individuals are high risk, with greater than 50% probability if they have any of the
following: history of acute ascending cholangitis, biliary pancreatitis or jaundice, presence of
CBD stone on regular US or cross-sectional imaging, dilated CBD on US (> 6 mm for patients
with intact gallbladders and > 8 mm for prior cholecystectomy), serum bilirubin greater than 4
mg/dL, elevated AST/ALT, elevated ALP and/or GGT. The intermediate risk patients range
between 10-50% odds of having a ductal stone if they meet any of these criteria: age older than
55, moderately dilated bile duct on US, or transient derangement of LFTs revealing abnormal
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liver enzymes. Low risk patient groups typically have no symptoms, normal liver enzymes, and
are not connected with the presence of any of the previously mentioned predictive factors.1,12,21
In these low risk cohorts “routine” pre-op ERCP prior to cholecystectomy is not justified
and likely to cause more harm than good. It carries the potential for causing PEP, especially in
young people with nondilated bile ducts, and is not cost-effective.18,19 Scoring systems are
essential to classify patients according to their relative risk of having bile duct stones in order to
reduce the amount of unnecessary pre-op ERCPs, while at the same time raise the rate of positive
intra-operative diagnoses.1 Recommended guidelines for investigating low or moderate risk
choledocholithiasis are not standardized but high risk patient groups should go on to receive
further workup and treatment.13
In a prospective population-based cohort study of 1,171 patients, authored by general
surgeons, the predictive value of bilirubin levels and serum ALP sampled 1-4 weeks before
patients underwent cholecystectomy were assessed as relevant biochemical markers for
concomitant ductal stone risk. In patients with raised bilirubin or ALP there was an occurrence of
CBD stone in only 42% of them. Normal bilirubin and ALP levels in patients equated to only 6%
risk for ductal stones. The limited value of ALP and total bilirubin as pre-operative predictors
has to do with several mechanisms. Ductal stones that are not completely obstructive might not
increase the body’s bilirubin and may produce false negative values. Stones may spontaneously
move to and from the CBD in the time period between blood draws and procedure, resulting in
both false negative and false positive numbers. Biliary sludge and microscopic stones in the
biliary tree could increase bile viscosity, triggering increased levels of both ALP and bilirubin,
but can go undetected on intraoperative cholangiogram (IOC) since they’re washed out into the
duodenum by contrast injected, producing a normal IOC image. The high number of false
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positive and false negative findings implies that other processes are responsible for increasing
ALP and/or bilirubin other than ductal stones. Spasticity or stenosis of the sphincter of Oddi may
cause increased LFTs and biliary colic even without actual choledocholithiasis.20 See Appendix
tables 1 and 2 for four different risk groups stratified based on clinical, lab, and ultrasound
findings and their suggested diagnostic and treatment pathways.19
Investigation and Diagnosis of Gallstone and Biliary Disease with Imaging
In spite of the fact that significant overlap exists between clinical presentations of
gallstone-related pathologies, the distinction between disease states can be accomplished with a
mixture of clinical, laboratory, and imaging studies.12 The first critical step in properly managing
CCL is arriving at a good diagnosis so that unplanned procedures, unnecessary invasive exams,
and undertreatment are all avoided.6 Controversy exists regarding the work-up of patients with
suspected bile duct stones because there is no clear consensus on the most appropriate way to
arrive at a diagnosis.1 Whenever there is a diagnosis cholelithiasis, the possibility of biliary
ductal stones should always be considered even without symptomatic presentation. Patient
education and discussion of how to potentially manage ductal stones is warranted in those with
planned elective LC for recurrent biliary colic.12
For initial imaging to investigate gallstone disease, right upper quadrant (RUQ) US is
standard. Cholelithiasis will be visualized as either single or multiple stones without associated
acute gallbladder inflammation/infection features. Asymptomatic stones are mobile in the
gallbladder and high attenuation of them results in formation of an acoustic shadow. Sonographic
scans revealing gallbladder wall thickening, pericholecystic fluid, duct dilation, or a stone
impacted in the neck are all signs of acute cholecystitis. The presence of sludge or gallstones are
not diagnostic however, because some patients may have small stones obstructing the cystic duct
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that escape detection. An important finding is ultrasonographic Murphy’s sign elicited by
ultrasound probe pressure over that anatomical landmark causing the patient localized tenderness
or severe pain.12 If the transabdominal US is equivocal then proceeding to a hepatobiliary
scintigraphy radionuclide scan abbreviated ‘HIDA’ is the next step to assess bile flow excretion,
cystic duct patency, and gallbladder function via ejection fraction to rule cholecystitis in or out.22
While US is the predominant diagnostic imaging for gallstone problems with reliable
success, visualizing ductal stones is not as straightforward.12 The optimal means for investigating
and working up CCL is still debated, especially as it pertains to acquiring an established preoperative diagnosis versus incidental intraoperative diagnosis.1,5 Despite the fact that a variety of
imaging modalities may predict the presence or absence of CBD stones pre-procedure, the most
precise methods are MRCP and ERCP, which are either too invasive, costly, or not readily
available in clinical practice.20 Until recently, the gold standard for imaging the bile ducts was
ERCP, but now MRCP rivals it in specificity and sensitivity in numerous clinical scenarios.18,19
ERCP has evolved into a principally therapeutic modality in endoscopy centers and is still the
best nonsurgical method for clearing a biliary mechanical obstruction that may be associated
with CCL.18
Another goal of risk stratification with preoperative predictive parameters is to reserve
more expensive or invasive imaging for higher-risk patients such as IOC, MRCP, or endoscopic
ultrasound (EUS). Traditionally, cholangiography during an intraoperative route was considered
gold standard for diagnosing choledocholithiasis, however with recent advances in radiological
technology, MRCP is now used more extensively to visualize intraductal stones.6 MRCP is a
convenient diagnostic tool that combined with a well-validated risk stratification scoring system
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would optimize the utilization of even more invasive/expensive diagnostic modalities like
ERCP.1
Since laparoscopy techniques took over as the dominant minimally invasive treatment
method, a preoperative CBD stone diagnosis has become progressively favorable.6 In patients
undergoing cholecystectomy, intraoperative cholangiography (IOC) is considered crucial by
most surgeons to detect concomitant CBD stones.16 At the present moment, not all centers
routinely perform IOC, it is done on a selective basis. The benefits of selective IOC are shorter
operating time and less perioperative complications at the expense of increased readmission rates
if CBD stones are found.6 With IOC, unlike a typical x-ray plain film with one picture, contrast
medium is injected and a live video of the bile ducts in real-time is recorded. The cholangiogram
is also valuable because it demarcates biliary duct anatomy, helps facilitate dissection, prevent
biliary tract injuries, and identify other abnormalities. More importantly the goal of IOC is to
reduce the incidence of bile duct injury, which is the most common complication of laparoscopic
cholecystectomy (LC). IOC may decrease the risk of bile duct injury during LC by helping to
avoid misidentification of the CBD.15
When used routinely laparoscopic IOC is still safer and more cost-effective than ERCP.15
However, some disadvantages of IOC are high false positive rate, longer operating room time,
and may not be feasible to obtain for a variety of technical reasons. An intraoperative diagnosis
of ductal stones necessitates CBD exploration (done laparoscopically) or referral for postoperative ERCP.16 A National Institute of Health (NIH) consensus article recommends that for
any patient with clinical suspicion for CBD stone prior to LC, a pre-operative ERCP should be
done instead of imaging the ductal system during surgery. The benefit being that detailed biliary
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anatomy would be available prior to removing the gallbladder and the need to perform difficult
laparoscopic CBD exploration is eliminated.15
For patients treated with endoscopic sphincterotomy (EST), the presence of residual
stones may be underestimated from the last cholangiogram performed right after stone extraction
because of many air bubbles entering the bile duct from the hole cut open at the ampulla of
Vater. Post-EST treatment is commonly followed up with a nasobiliary catheter in the supine and
prone positions with repeat cholangiograms to look for residual stones and if positive another
ERCP is required. As of recently, ultrasonography of the ducts has been used for identifying
residual stones, specifically if the bile duct is dilated. Intraductal ultrasounds can correctly
distinguish bile duct stones from air bubbles.23 But traditional abdominal sonography is not an
optimal imaging modality to diagnose CBD stones because of its poor sensitivity due to presence
of duodenal gas obscuring the imaging field.12,21 Even when comparing similar yet two distinct
sonographic imaging modalities, choosing the appropriate one is essential to obtain a clear
picture of what is actually happening in the biliary tree versus what’s just artifact. Although
regular ultrasounds are the least invasive, it seems that in order to gain accurate CBD imaging,
slightly more invasive imaging technology is required to study the ducts. It’s apparent that the
main role of traditional RUQ US is to investigate cholelithiasis and cholecystitis without
suspicion for stones in the biliary tree. But in terms of assessing and working up bile duct stones,
the predominant use of transabdominal US is measuring CBD diameter to document dilatation.
Evaluation of suspected CBD stones can be achieved with high sensitivity and specificity
using MRCP which is better than US, but costs 4 times as much and not accessible at all
facilities.16,19 Selective use of noninvasive MRCP when appropriate can decrease the amount of
unnecessary ERCP and CBD explorations in those with presumed choledocholithiasis.16,18
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MRCP has practically replaced ERCP for diagnosis of biliary disease in most medical centers,
with ERCP being used solely for treatment purposes.18,19 Comparatively MRCP is less invasive,
faster, less costly, less reliance on the operator than ERCP, and also does not require sedation.18
While MRCP imaging is noninvasive and highly sensitive for ductal lesions, it is still relatively
costly and does not offer any therapeutic benefit, so it has a limited role following endoscopic
stone extraction.23 Two drawbacks of both MRCP and ERCP is that small stones less than 3 mm
may be missed and intraluminal CBD abnormalities can mimic stones.18 This would lead one to
believe that patients with small sized stones do not have choledocholithiasis, especially in the
absence of symptoms. On the contrary, patient’s imaging may inaccurately reveal presence of
ductal stones when there is just an irregularity or benign artifact that misleads the radiologist.
The use of EUS is a newer tool recently added to the list of diagnostic options but is not
widely available among many hospitals. Regular use of EUS is indicated for patients with
intermediate or high risk of choledocholithiasis.6 Both EUS and MCRP can accurately image the
biliary system without instrumentation of the ducts, an advantage over diagnostic ERCP.5 The
beauty of EUS is that it is a noninvasive imaging modality to visualize bile duct and gallbladder
stones with virtually no risk of causing pancreatitis.18 An anticipated future use of EUS is in a
two-stage sequence diagnostic approach whereby negative-MRCP individuals with intermediate
to high risk of CCL proceed to EUS.6
Abdominal CT scans play a limited role in detecting ductal stones due to its low
frequency of radiopaque stones and cut-off size, but rather may be advantageous for incidentally
locating silent stones.6 In general CT and US scans have limited accuracy for detecting CBD
stones. When working up patients with suspected choledocholithiasis, those two imaging studies
are primarily used to look for bile duct dilatation secondary to obstruction.18 After
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cholecystectomy it’s common for the CBD to expand in diameter upwards of 10 mm, therefore
US is not helpful in these cases, because the dilation is most often a result of the procedure and
not necessarily ductal stone(s). UpToDate recommends that for patients with prior
cholecystectomy presenting with biliary colic, liver test derangements, and uncertain US results
to progress to MRCP or EUS to confirm choledocholithiasis or alternative etiologies.21
Interestingly, in one third of patients with ductal stones, dilation of the bile duct is absent for a
few reasons. Some possibilities include early obstruction, small stones causing partial
obstruction, or proximal biliary strictures preventing the ducts from distending. Consequently,
some radiologists believe that MRCP should replace US and CT when evaluating for CBD
stones to avoid false-negative results, unneeded imaging, and delay in treatment.18
Comparison of Treatment Approach Techniques, Outcomes, Complications
When patients present with both gallstones and bile duct stones, effective treatment is
centered around two important questions: Should the gallbladder be left or removed? What is the
most effective approach for clearing the bile duct? It goes without saying the primary goal of
treating CCL is to accomplish ductal clearance with the least number of interventions, low
morbidity, and cheapest cost. Over the last 25 years as technology has advanced, the diagnostic
imaging and therapeutic approach to choledocholithiasis has been substantially improved with
minimally invasive techniques.1 No one therapeutic option has been proven superior to the other
and multiple different sequential treatment techniques are utilized in clinical practice, making it
more of a challenge to pinpoint the theorized ‘best approach.’ Attempts to synthesize current
available evidence on the management of CCL have previously failed to compare all minimally
invasive methods based on the sheer number of different approaches and combinations.24 The
main goal of this literature review section is to summarize the most common minimally invasive
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techniques utilized in real world practice and compare each one in terms of postoperative patient
outcomes, complications, and effectiveness in clearing the bile duct.
There are several treatment options for CBD stones at the time of laparoscopic
cholecystectomy (LC).25 If ductal stones are detected on imaging, current guidelines endorse
removal either before or at the same time as LC.13 LC was universally adopted as the gold
standard treatment of symptomatic gallstones in the early 1990s.6,26 Isolated cases of
asymptomatic cholelithiasis are not an indication for surgery, but presence of stones in the biliary
tree always requires treatment, even small stones need to be removed.21 When CBD stones are
present in addition to gallstones, it makes a standard LC much more arduous and timeconsuming. It’s important to be aware of ductal stones pre-operatively because it enables better
planning and allocation of essential resources.20
Long before the advent of laparoscopic approaches that revolutionized the management
of concurrent gallstones and ductal stones, patients were cured with a single surgical operation.17
Prior to the inception of endoscopic treatment practices for choledocholithiasis, surgical
exploration of the CBD and open cholecystectomy were standard of care with low morbidity and
mortality rates, 1-3% chance of retained stones, and revision surgery needed in 10% of cases
over long-term follow-up.27 During these ‘open cholecystectomies’ large abdominal incisions
created an excellent surgical field to easily remove the gallbladder and its stones, as well as
perform an IOC. If ductal stones were visualized on IOC, the surgeon proceeded to opening up
the CBD and treating choledocholithiasis at the same time right then and there. Since
laparoscopy has become the dominant technique in managing CCL, surgeons began to lose their
surgical field and skills over time as they moved away from opening and exploring the CBD.17
Nowadays this type of surgical intervention is reserved for individuals following unsuccessful
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less invasive procedures.27 It makes sense that over time the majority of surgeons now opt to
perform laparoscopic techniques in managing cholelithiasis, cholecystitis, and
choledocholithiasis because patients have better long-term outcomes and quality of life.
Abdominal surgery and cutting open the abdominal wall are invasive and can cause
postoperative issues worse than the initial disease requiring treatment. Risks and benefits need to
be weighed on an individual basis to ensure that either closed laparoscopic or open surgical
methods are appropriate for each specific patient.
In the current laparoscopic era, the cornerstone treatment methodology is to manage CCL
as minimally invasive as possible.26 ERCP was originally created in 1974 to remove CBD stones
in patients without their gallbladder and signified a breakthrough technique because it allowed
for biliary stone extraction after open cholecystectomy without the need for repeat surgery.17 In
the 1980s ERCP became the go-to technique for acute choledocholithiasis presentations with
relatively high success rates of endoscopic biliary duct clearance.26 Today, use of ERCP is on the
rise and widely accepted as a mainstream treatment choice for endoscopically removing ductal
calculi.8 ERCP is both diagnostic and therapeutic in nature. When used to study the ducts
draining the liver, gallbladder, pancreas and drainage opening termed the papilla, contrast dye is
injected and x-ray images are taken. More often it’s done for therapeutic purposes and various
treatments can be performed via ERCP endoscope including sphincterotomy, stone removal,
ductal stenting, balloon dilation, or tissue biopsy. ERCP sensitivity is estimated to be 80–93%
with a specificity of 99–100% for choledocholithiasis.21 ERCP is the most dangerous technique
in terms of morbidity and mortality routinely performed by gastroenterology endoscopists with a
post-ERCP pancreatitis (PEP) rate ranging from 3-5%. It has a low yet persistent morbidity rate
of 10% and mortality rate slightly greater than 0.5%, chiefly related to endoscopic
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sphincterotomy (EST) complications.1 Regardless of its limitations and disadvantages, when
treating acute calculous biliary disease, the role of ERCP remains central and optimal.26 The
timing of ERCP matters and also comes into question whether it’s performed pre-operatively,
intra-operatively, or post-operatively.24
EST involves cutting the sphincter of Oddi muscle between the pancreatic and common
bile duct to create a small opening for advancement of the endoscope and catheter, and is most
commonly used for removal of stones or other blockages. After sphincterotomy, stones can be
retrieved from the duct and swept into bowel for elimination using different specialized balloons
or baskets attached to the catheter.21 EST and other endoscopic techniques used for stone
fragmentation and extraction are commonly performed to clear the CBD, but more than one
procedure may be needed, especially in challenging cases.23 It is well established that biliary
sphincterotomy dilation improves the success rate for complete stone removal and not leaving
residual stones behind.17 Meanwhile, EST is associated with late complications of recurrent stone
formation and cholangitis infection.5 Even skilled endoscopists experience complications
associated with ERCP and EST including bleeding, infection, pancreatitis, perforation,
cardiopulmonary events, sphincter of Oddi inflammatory changes or ampullary stenosis.8,24
Since there is a spectrum of treatments for CBD and associated gallbladders stones,
various procedure strategies and sequences will be discussed, with emphasis on the most relevant
and commonly performed ones. Their outcomes in terms of success rate to remove all stones,
prevent recurrent stones, avoid complications and conversion to other procedures, reduce
morbidity and shorten hospital stay will be compared and contrasted. There is much debate
throughout the literature for decision analysis regarding whether one-stage or two-stage
approaches are more efficacious, with a growing body of evidence supporting one-stage for its
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suggested benefits of decreased hospital stay and costs.24 Treatments for CCL can typically be
divided into two different types: one-step or two-step. The most notable treatment options found
in recent literature are: LC after endoscopic treatment (two-step procedure), endoscopic
treatment after LC (two-step procedure), LC plus laparoscopic CBD exploration simultaneously
(one-step procedure), LC combined with simultaneous intraoperative ERCP (one-step
rendezvous method), and LC combined with intraoperative endoscopic sphincterotomy (IOES)
(one-step procedure).24,25,28 All of these interventions will be discussed next, focusing on the data
and evidence comparing them to one another.
Majority of hospitals worldwide prefer and rely on ERCP as the least invasive way to
drain the CBD.6,17 For patients with high probability of CBD stones, there is a propensity to use a
two-stage approach with pre-operative ERCP plus biliary sphincterotomy to clear the ducts
followed by LC in clinical practice.1,6,24,28 This approach is popular because the surgeon is
assured a clear duct without distal obstruction which reduces the risk of bile leak after the
operation and need for further postoperative procedures.29 Preoperative endoscopic bile duct
clearance sounds appealing in that it makes successive LC easier to perform. But when a metaanalysis compared pre-op ERCP followed by initial LC in a multi-step sequential treatment,
higher morbidity and mortality was demonstrated. By having two separate procedures the
complications are additive.12 Another drawback is having the patient endure two different
anesthesiology sessions which also contributes to higher overall complication rates.6 Moreover,
there is a higher conversion rate from laparoscopic to open surgery when ERCP is done first,
followed by subsequent LC, causing increased difficulty to perform cholecystectomy.6,12
A new emerging treatment technique called laparoendoscopic rendezvous (LERV) is an
appealing single-stage option being used for difficult or unusual CCL presentations in terms of
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anatomical complexity, numerous comorbidities, and even pregnancy.28 LERV consists of
simultaneous intraoperative ERCP with LC enabled by papilla visualization and cannulation
through laparoscopic placement of a guide-wire inserted through the cystic duct into the
duodenum see appendix image 1.6,18,28 In LERV the gallbladder is removed laparoscopically
while a CBD stone is concurrently cleared endoscopically via selective CBD cannulation (see
appendix image 2).28 The benefit of this is selective CBD cannulation of the ampulla of Vater
without the risk of unintended pancreatic duct cannulation and irritation whereas ERCP contrast
medium may be inadvertently injected into the pancreatic duct under pressure due to its
retrograde injection (see appendix image 3).28 Hypothetically there are significant advantages of
this combined technique over the traditional two-stage approaches in terms of clinical results
aside from necessitating coordinated effort between surgeons, endoscopists, and operating room
technicians.6,18 This combined radiologic-endoscopic same day LC with ERCP procedure
commits both the biliary endoscopist and their assistant(s) to spend a considerable amount of
time in the operating room which is not ideal from a financial perspective.18
Nonetheless, the rendezvous method has shown promising results demonstrating minimal
invasiveness, reasonable learning curve, lower incidence of complications like perforation,
bleeding, and post-ERCP pancreatitis. Furthermore, it has been associated with less cost and
technical difficulties, and shorter hospital stay as it does not lengthen hospitalization of patients
undergoing routine LC. Many literature reports have also confirmed its safety and excellent CBD
clearance rates.6,28 One drawback of intraoperative ERCP is the potential for bowel insufflation
and bile leakage via the cystic duct, which could be worsened if the procedure duration is
prolonged.28 A data review of 27 studies including over 800 patients comparing the rendezvous
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technique to other procedures found it to have a mean ductal clearance rate of 92.3% and fewer
complications with percentages ranging from 1.6-7%.6
In a surgery case report, the authors aimed to explore the utility of using LERV and its
efficacy for distinctive clinical scenarios that carry higher risks where conventional procedures
would be unsuccessful. Such difficult situations include anatomical difficulty in old age,
pregnancy, multiple comorbid disease, postlaparotomy and sigmoid resection. To the author’s
knowledge, they had the first reported case of successful rendezvous treatment of CCL in a 23year-old first trimester pregnant patient. Overall LERV represents an attractive alternative choice
for higher risk individuals and has been shown to have far less postoperative complications,
shorter hospital stays and decreased medical costs.28 Six RCTs reviewed in a recent metaanalysis prospectively compared LERV and pre-op ERCP found that the rendezvous method had
shorter hospital stay and reduced cases of endoscopy-related pancreatitis, while morbidity and
stone clearance were nearly equivalent. Published results of a different comparative study of 200
patents also suggested the advantage of LERV over pre-op ERP in regards to hospital stay which
is beneficial for the facility economically in the current reimbursement environment.6
Another one-step procedure is simultaneous LC with LCBDE which is desirable to
perform for the fact of not needing to conduct multiple procedures.6 This strategy of
laparoscopically clearing the bile duct offers a novel and feasible approach for the surgeon to
resolve both cholecystitis and choledocholithiasis in one sitting, while avoiding the long-term
sequelae associated with sphincterotomy and minimizing the risks of post-ERCP
complications.5,6 Utilizing LCBDE also reduces the need for more anesthesia, decreases hospital
stay, and boasts exceptional stone extraction success rates more than 90%.6 LCBDE has an
excellent reputation throughout the literature for its effectiveness to manage CCL but widespread
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acceptance of its use is far off due to lack of expertise availability.1 However, when comparing
LCBDE in a head-to-head RCT directly against LERV there were no differences reported
between both one-step procedures in terms of success rate, surgery duration, complications,
retained stones, hospital stay and costs. A meta-analysis reviewing the rendezvous method
merged studies to compare LCBDE to LC either preceded or followed by ERCP and did not find
any statistically significant differences in patient outcomes.6
An analysis of 21 different studies of exclusively randomized controlled trials (RCTs)
was constructed into an advanced decision tree with a series of statistical analyses and calculated
probabilities comparing four different treatment strategies in patients planned to undergo LC: 1)
Laparoendoscopic Rendezvous 2) Laparoscopic CBD Exploration 3) Pre-Operative ERCP 4)
Post-Operative ERCP (see appendix figure 1).24 Data extraction was utilized for a base case
analysis, deterministic analysis, and probability sensitivity analysis (see appendix graphs 1–4).24
The base case analysis assigned a value of 1.0 for complete bile duct clearance without
complications and 0.5 with complications. LERV had the highest utility output of 0.90 overall
(0.87 no complication probability, 0.06 complication probability). Laparoscopic CBD
Exploration (LCBDE) ranked second at 0.87 (0.82 no complication probability, 0.10
complication probability). Pre-Operative ERCP utility score was 0.84 (0.78 no complication
probability, 0.11 complication probability). Post-Operative ERCP ranked last at 0.78 overall
(0.71 no complication probability, 0.13 complication probability). Using the same
definitions/values of 1.0 and 0.5, the probabilistic sensitivity analysis revealed an equal utility
output of 0.57 between LERV and LCBDE, but the rendezvous technique had a higher treatment
selection frequency of 39.93%. LCBDE was selected 36.11% of the time, pre-operative ERCP
20.67% and post-operative ERCP only 2.99%. Length of hospital stay was an average 3.78 days
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for the LERV approach compared to 4.40 days for LBCDE. Pre-operative ERCP was found to
have the longest hospital stay of 6.50 days followed by 5.60 days for post-operative ERCP.24
This evidence suggests that the LERV single stage approach could have a marginal
advantage over other treatment techniques in terms of primary duct clearance, complications, and
hospital stay duration. This review found that LCBDE had better success rates in clearing the
biliary ducts and shorter hospital stay than pre-operative ERCP which is consistent with other
systematic reviews and meta-analyses directly comparing the two procedures.24 Morbidity rates
amongst all these treatment options were not significantly different. While LCBDE seems
promising in comparison to ERCP, in actual practice this technique is not a universally available
skill and at the same time, surgeons who perform LC are not always trained to do ERCPs.1,24
It’s not clear yet if the rendezvous technique offers superior advantage because of merely time
savings or reduced complications, rates of cystic duct leak, or need for sphincterotomy.24
In a similar type of study evaluating 15 different RCTs, the authors followed the
preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines to
compare CCL interventions with computed quantitative statistical analysis. Outcomes assessed
were stone clearance from the CBD, success rate for stone clearance, retained stones,
complications, postoperative morbidity, pancreatitis, conversion to other procedures, conversion
to open procedure, conversion to laparotomy, mean total cost, total operating time, hospital stay,
and mortality. Four cohort groups compared two different procedures on a variety of outcomes in
patients also receiving LC. The following cohorts are 1) pre-op ERCP vs. LCBDE 2) post-op
ERCP vs. LCBDE 3) LCBDE vs. IOES 4) IOSE vs. pre-op ERCP and results will first be
discussed for each cohort (see appendix table 3).25 The clearance rate for pre-op ERCP and IOES
were similar with an odds ratio of 0.77 and 95% confidence interval (CI). Average operating

Management of Gallstones and Bile Duct Stones 31
time was longer for the IOES group at 127 minutes versus 100.20 min for pre-op ERCP which
was expected but not statistically significant. One death was reported in the IOES group but
overall complication rates were relatively comparable, but incidence of ERCP related
complications were much higher at 4.2%. The number of patients whose LC was converted to
open surgery was 3% for both groups. In the post-op ERCP versus LBCDE cohort, stone
clearance, postoperative morbidity, and conversion to other procedures were similar. Total
operating time was nearly the same with post-ERCP taking 126.5 min and LCBDE 124.4 min.
Median hospital length for post-op ERCP was 5.6 days, slightly longer than LCBDE at 3.7 days,
but this difference was not statistically significant. Next, when comparing pre-op ERCP versus
LCBDE, stone clearance, conversion to other procedures, and total operating time (133.77 vs.
119.15 min) were again similar for both. Postoperative morbidity was lower for the pre-op ERCP
treatment, but mortality rates were comparable. Lastly, the comparison between IOES and
LCBDE revealed similar stone clearance rates of 94.3% for IOES and 90.6% for LCBDE.
Similar rates of operative morbidity at 9.4% for IOES and 6.3% for LCBDE. Conversion rate to
other procedures was also comparable with 6% for IOES and 9% for LCBDE. Again, hospital
stay (IOES 3.7 vs. 3.4 days LCBDE) and total operating time were similar between both
procedures (IOES 104.2 vs. 95.4 mins) (see appendix table 4).25
One of the most comprehensive up-to-date reviews on treating CCL in the literature that
carefully and rigorously selected 16 RCTs with 1,758 patients put together by the Cochrane
group found no significant differences between morbidity and mortality for open surgery versus
ERCP clearance. Similarly, there were no substantial differences in the primary outcomes
between LCBDE and pre-op ERCP. But there was a detectable difference in amount of retained
stones among LCBDE (9%) and post-op ERCP (25%).6,29 The main downfall of ERCP after LC
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is failure to completely clear the bile duct post-operatively and then repeat additional procedures.
The strategy to selectively use IOC and ERCP after LC is logical only for lower risk patients.
Post-op ERCP is also relevant for those with misdiagnosed CBD stones, discovered only after
gallbladder removal.6 Patients who present with biliary colic, cholestasis, or gallstone
pancreatitis and have elevated LFTs but then show a quick trend down toward normalized values
are probable to have passed the offending stone(s). In these cases, surgeons should proceed to
LC first with an IOC without prior ERCP. If the results of the cholangiogram show a filling
defect, only then should the patient undergo post-ERCP the next day for EST and stone
extraction.18
Selection of therapeutic option should also take into account unique patient anatomy of
the cystic and common bile duct (tortuous shape or large diameter), presence of strictures,
previous surgical history, and number and size of ductal stones.5 Best practices should reserve
the use of therapeutic ERCP in patients with CBD stones only in selected doubtful cases due to
the potential for false-positives and complications. To resolve isolated cases of
choledocholithiasis without gallstones the optimal treatment is ERCP alone. Sole ERCP is
required urgently for patients with severe comorbidity unfit for surgery presenting with CBD
obstructive symptoms like acute ascending cholangitis or biliary pancreatitis.6
The Role of Cholecystectomy Before or After Bile Duct Clearance
The frequency of acute cholecystitis following endoscopic CBD stone extraction is
17%.10 After a diagnostic or therapeutic ERCP about 10% of patients develop acute
cholecystitis.1 Therefore, cholecystectomy is commonly performed as an adjunct treatment
intervention alongside endoscopic CBD stone removal to prevent not only cholecystitis, but also
biliary colic, pancreatitis, or calculi recurrence.10 In patients with choledocholithiasis and an
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intact gallbladder, the necessity for elective cholecystectomy either before or after endoscopic
bile duct stone clearance is controversial.23 Regardless of disagreement, LC plays a pivotal step
in the whole process to manage CCL.6 Patient age and comorbidities should be accounted for
when deciding to remove the gallbladder based on operative risk.23
In a prospective randomized trial of Chinese patients older than 60, the intervention
group that received LC with ductal clearance had only 7% biliary complications reported. The
control group (expectant gallbladder in situ group) that only received bile duct clearance had
24% of future events related to cholangitis, obstructive jaundice, cholecystitis, or biliary pain. A
retrospective analysis of more than 4,500 patients hospitalized for bile duct stones where half
received cholecystectomy immediately after ERCP and the other half on a ‘wait-and-see’ policy
showed that patients waiting for delayed gallbladder removal had tenfold increased risk of
repeated negative biliary tract events.17 One study observing patients after EST with expectant
gallbladder management found that all cases of acute cholecystitis took place within the first
year, implying that early gallbladder removal may be warranted.5,17 Additionally, performing LC
later down the road is problematic and associated with increased rates of conversion to open
surgical cholecystectomy.26 Other studies utilizing randomized trials have reported similar
findings with more sequelae in patients who did not undergo cholecystectomy shortly after
choledocholithiasis treatment.17
In asymptomatic patients there are a few exceptions to just observing for those at high
risk of experiencing biliary complications. Prophylactic cholecystectomy should be initiated in
those with silent cholelithiasis for the following reasons. Individuals with large gallstones greater
than 3 centimeters. Patients with sickle cell disease because problems with stones can be
challenging to differentiate from sickle cell crisis symptoms or complications. Biliary sludge and
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gallstone formation occurs more frequently after organ transplant, therefore patients who have
received a donated heart, lung, kidney, or pancreas are more at risk for acute cholecystitis in the
2 years following transplant surgery. Patients expected to undergo another type of abdominal
surgery, such as bariatric surgery, should also receive simultaneous gallbladder removal.3
Based on the available data, most experts believe that majority of patients should receive
elective LC after endoscopic ductal clearance to prevent further biliary issues or manage
cholecystitis if already present. Except in patients who are high-risk candidates for potential
serious complications with LC, then they should be managed more carefully without adding
additional procedure risk.26 One argument for more conservative management to leave the
gallbladder in place is that several studies report substantially improved motility after EST
making the gallbladder more capable of flushing away early sediment thereby preventing new
stone development. But in general, for younger or middle-aged otherwise healthy adults it is
recommended to undergo LC prior to or after bile duct clearance.23
Risk Factors for Post-Operative Stone Recurrence
The overall recurrence rate of CBD stones after endoscopic stone removal is 13%.10 True
recurrence after stone clearance and the numerous risk factors involved are not well defined.
Accurate recurrence frequency is difficult to determine because it would require life-long follow
up and account for both asymptomatic and symptomatic cases. One study found that 39% of
recurrent bile duct stones after 2-year follow-up occurred in patients without symptoms, and
therefore detected by routine screening LFTs and US. Identifying patients who have significant
predisposing factors for recurrence would allow for closer follow-up, quicker intervention, and
potential preventive actions to decrease repeated stone formation and its associated
complications. Immunosuppressed and elderly patients are two populations at higher risk for
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more serious subsequent choledocholithiasis complications such as cholangitis, biliary sepsis or
cirrhosis, or even death.23
While most recurrences happen in the first 3 years post procedure, the time limit between
what constitutes residual and recurrent is arbitrary.8 It’s quite difficult to discriminate whether
post-operative stones are recurrent or residual because of detection within a short time interval
after ERCP in the perioperative period.30 Throughout the literature, several studies are in
agreement that in order for stones to be considered ‘recurrent’ following operative treatment, a
minimum threshold of 6 months is required.10,14,30 Any findings of CBD stones before the 5-6
month threshold is defined as residual and occur as a result of failure to remove all stone
fragments during the initial intervention. Residual ductal stones differ in composition from true
recurrent primary CBD stones.23 But whether most recurrent CBD stones after cholecystectomy
are the result of migrated gallbladder stones during the procedure into the biliary tree or newly
formed ductal stones is not always certain.21,30
A list of known risk factors for recurrent bile duct stones in patients who underwent
cholecystectomy is dilated CBD, angulation of the CBD, multiple or large ductal stones,
cholelithiasis, biliary infections or strictures, papillary stenosis, periampullary diverticula (PAD),
surgical history of open cholecystectomy, lithotripsy, and advanced age.8,10,14,23,30 In a European
study in the World Journal of Gastrointestinal Endoscopy, researchers were focused on
evaluating the recurrence of symptomatic choledocholithiasis over the long-term in patients who
underwent ERCP and EST. They investigated both anatomical measures and stone characteristics
contributing to recurrence.8 The size and number of stones has been explored in multiple studies
and the diameter of ductal stones, larger than 10 mm, is an independent risk factor for recurrent
choledocholithiasis after ERCP. The bigger the stone diameter the larger the bile duct dilatation.
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This affects the normal bile duct motor function setting up an environment that is favorable for
pigment stone formation because of accompanying cholestasis and bile duct bacterial infection.14
Patients who had difficult lithiasis or unfavorable stone characteristics such as large size
requiring mechanical lithotripsy had higher incidence of CBD stone recurrence after endoscopic
extraction.8 For patients with numerous and/or large stones where lithotripsy may have been used
or failed, initial incomplete removal as the source of post-operative CBD stones should be
considered.30 When patient’s bile ducts are challenging to clear due to large stones and
lithotripsy is utilized, this may lead to small residual stone fragments lingering in the CBD not
visualized on the cholangiogram. These tiny stones form the core of a new stone that develops
over time which is a hidden risk factor for recurrent choledocholithiasis and lithotripsy is an
independent risk factor.14 Patients treated for a single CBD stone with stone removal followed by
LC had a much high actuarial probability of staying free of recurrent symptomatic stones at
96.8%. But patients treated for multiple CBD stones, 2 or more ductal stones, experienced
recurrent symptomatic choledocholithiasis 16% of the time. Presence of many bile duct stones is
proposed to be an independent risk factor for recurrence.10
Obstructive bile duct lesions such as papillary stenosis and biliary strictures are both
correctable risk factors for stone recurrence. An insufficient papillary orifice may occur after
sphincterotomy due to excess coagulation current during the procedure or insufficient incision.
Bile duct stenosis is highly associated with risk for stone recurrence and aggressive stricture
therapy involving dilatation or stent placement should be pursued.23 PAD is another obstructive
lesion also found to be associated with higher rates of recurrence.8 This type of risk factor is
much more difficult to correct and surgical removal of diverticulum is rarely done.23 Diverticula
alter the terminal bile duct or sphincter and quantitative cholescintigraphy in PAD patients has
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shown slower biliary emptying. Sluggish biliary emptying and bile stasis is the main underlying
mechanism in PAD creating an environment suitable for repeated stone formation.10,23 Patients
with type I or II PAD also had significantly lower rates of actually not developing recurrent bile
duct stones (80.5%), whereas 93.2% of individuals without diverticulum never had repeat
episodes of stone recurrence. Patients with type III PAD also had far less events of stone
recurrence similarly to those without any diverticulum. Some studies have reported that PAD is
related strictly to formation of recurrent primary brown pigment CBD stones, but not secondary.
Obstructive lesions like PAD occur in patients aged 50 and older in 75.5% of cases.10
Patients with previous endoscopic biliary interventions for benign or malignant disease
are also prone to the development of primary bile duct stones due to poor drainage related to
either sphincterectomy stenosis or a chronically dilated CBD.12 Bile is commonly colonized with
bacteria after EST with about 60% positive cultures. Bile stasis and bacterial contamination of
the markedly dilated CBD play a role in the pathogenesis of recurrent brown pigment stones.23
CBD dilation greater than 13 mm was also found to be a significant risk factor predisposing to
repeat stone development.8 Dilatation of the CBD long-term leads to decreased smooth muscle
retraction, suboptimal function, bile excretion difficulty which in turn all promote the formation
of stones due to secondary cholestasis and bacterial infection. The risk for recurrent ductal stones
is roughly four times higher in patients with a CBD diameter of 15 mm or larger. CBD diameter
is a confirmed risk factor for recurrent biliary stones; however, the exact size threshold has been
not determined. In terms of biliary anatomy, the angle of the bile duct is inversely proportional to
the speed of bile flow. Thus, prolonged biliary drainage results in excess bile concentration
followed by subsequent cholesterol saturation and worsened bile duct function setting up a series
of reactions and conditions conducive to recurrent stone formation. Current data has not
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established a specific CBD angulation degree linked with high risk but some studies estimate
numbers such as 130º, less than 135º or 145º.14
The minimally invasive treatment strategy used for patients with CCL also comes into
question when looking into why patients get repeated stones even after having their gallbladder
removed and bile ducts cleared. Individuals who underwent EST are more prone to bile duct
inflammation, papillary stricture, choledochal dilatation, diverticulum, duodenal contents
returning to the bile duct, or foreign body in the CBD. All of these may contribute to ductal stone
recurrence after stone extraction. Some studies have shown that small incision EST can help
prevent the recurrence of ductal stones. A few retrospective meta-analyses have reported that the
rate of recurrence is higher in the EST treatment group compared to lower rates in the LCBDE
group because of the preservation of sphincter of Oddi function. Patients who are subjected to
undergo multiple ERCP procedures have higher incidence of retrograde infection due to
aggravation or injury to the sphincter of Oddi which further contributes to repeated stone
formation necrosis of bile duct epithelium. In elderly patients, biliary stenting may be a better
alternative choice than EST due to the associated risks with cutting the sphincter muscle. The
problem with long-term stent placement is induction of bacterial proliferation which encourages
pigment stone formation.14
Over a 10-year follow-up after initial EST procedure, any recurrent stones detected were
all brown pigment stones. The chemical composition of bile may be altered by a variety of
mechanisms including cholestasis, bacteria, and papillary stricture. Another possibility is that
cholangiography may miss small stone fragments which leads to accumulation, aggregation, and
eventual recurrence. Some congenital factors such as sex, age, metabolism, anatomy, and
genetics may play a part in causing recurrent choledocholithiasis. Higher estrogen levels leading
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to delayed gallbladder cholestasis in women makes them more likely to form cholesterol crystals
and development of ductal stones. Increasing age is considered an independent risk factor for
recurrent stones, with a high rate of 30% choledocholithiasis in people over 65. Metabolic
syndrome issues like obesity, physical inactivity, abnormal lipid breakdown, high calcium,
insulin resistance, and diabetes are all factors that persist even after CCL treatment and stone
removal. Therefore, these conditions or disease states are risk factors of importance that are
associated with higher rates of repeat CBD stone episodes.14
Patients who required a repeat ERCP less than 5 years after their first EST were at
increased risk for subsequent stone episodes.8 It is hypothesized that leaving the gallbladder in
situ after EST procedure can lead to CBD stone recurrence secondary to stone migration out of
the cystic duct. This dilemma is the basis for disagreement as to whether or not elective
cholecystectomy before or after endoscopic treatment is best practice.23 The gallbladder function
to excrete bile and flush the biliary tract is lost when patients undergo prophylactic
cholecystectomy which can increase the risk for recurrent choledocholithiasis. Detection of
cholesterol stones specifically in the CBD is another strong independent risk factor for postoperative recurrent ductal stones.30 Individuals with a prior history of biliary surgery (open bile
duct exploration and T-tube drainage) may have bile duct wall damage, scarring, local adhesions,
or develop biliary strictures and inefficient bile excretion afterwards, all of which can play a role
in causing recurrent bile duct stones.14
Researchers in Korea investigated the rate of post-operative CBD stones in patients who
underwent removal of their combined CBD and gallbladder stone(s) with subsequent
cholecystectomy. Recurrent stones were confirmed during an endoscopic nasobiliary drainage
(ENBD) tubogram at follow-up after gallbladder surgery in which ductal stones were completely
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removed at initial ERCP. After cholecystectomy approximately 20.1% of patients had a positive
ENBD tubogram for post-operative CBD stones.30 Performing ENBD insertion after ERCP can
lower the recurrence rate of stones after CCL procedural treatment.14 Routine ENBD tubograms
may represent a safe, practical option compared to other more involved, expensive, or invasive
endoscopic exams to look for the presence of ductal stones early after cholecystectomy and avoid
redundant endoscopic procedures plus sedation in the absence of choledocholithiasis.30 In select
high-risk patient groups with many CBD stone recurrences, yearly observation with ERCP may
be warranted to avoid further repeat stones and consequent cholangitis infection. A group of
researchers suggests prophylactic ERCP annually for individuals who have had at least two
recurrent CBD stone events.23 Clear recommendations have yet to be established for routine
follow up in patients who have dealt with ductal stone recurrence, but careful monitoring should
occur with screening every 1-2 years.10,14 This type of annual screening is important to be able to
catch stones and treat them before they become problematic and cause serious complications.
Methods
To formulate this thesis paper, a significant database search was conducted utilizing
Google Scholar, PubMed, UpToDate, and the Augsburg Lindell Library search engines. Peerreviewed research articles were the primary source of information with majority of the studies
originating in the United States and are written in the English language. Articles were mostly
written and published in the last 20 years; the preset time filter ranged from years 2000–2021.
The majority of the meta-analysis review papers comparing treatment methods are very recent
within the last 5 years to best capture the most current minimally invasive techniques to treat
CCL. Article titles and abstracts were reviewed for the inclusion of both cholelithiasis and
choledocholithiasis. All abstracts were read thoroughly and if they were insufficient in helping to
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answer the research question relating to risk factors, diagnosis, workup, and management of
concurrent gallbladder and biliary issues then they were discarded. Exclusion criteria for articles
focusing solely on treatment interventions included studies that did not address both conditions
of cholelithiasis/cholecystitis and choledocholithiasis. Articles in question were read at length to
decipher if the information presented was related to the topic of this research review.
Additional articles were selected from the references cited in the initial studies found
from the original database search. The literature review detailed studies involving young to
middle aged adults as well as older adults, with only one or two articles mentioning elderly
populations. Most of the study designs included were RCTs, systematic reviews, meta-analyses,
prospective or retrospective studies, and comparative reviews. Keyword search terms and
common abbreviations included: “gallbladder and biliary anatomy,”
“cholecystocholedocholithiasis (CCL),” “cholelithiasis and concomitant choledocholithiasis,”
“common bile duct (CBD),” “pathogenesis of CCL,” “risk factors for CCL,” “diagnosis of
CCL,” “management of CCL,” “endoscopic treatment of CCL,” “comparison of procedures for
CCL,” “laparoscopic cholecystectomy (LC),” “endoscopic retrograde cholangiopancreatography
(ERCP),” “laparoscopic common bile duct exploration (LCBDE),” “laparoendoscopic
rendezvous (LERV),” “recurrent choledocholithiasis,” and “intraoperative cholangiogram
(IOC).”
Discussion
The ultimate goal of this paper is to present a cohesive review of recent data and evidence
regarding the most agreed upon minimally invasive endoscopic and surgical procedures effective
for treating patients with concomitant gallstones and bile duct stones. This comparative literature
review sought to determine which treatment approach is superior in the management of CCL. At
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the present moment, the consensus remains that not enough evidence is available to strongly
stand behind any one treatment strategy as the gold standard. Although a two-stage sequential
approach is used more prevalently throughout real-world clinical practice, the literature reports
many favorable outcomes for a single-step procedure. The main reason for this preferential
treatment is based off the need to reduce discomfort and risks for patients alongside the
economic pressure to limit costs and resources being used.6
Although the most commonly employed strategy of ‘pre-op ERCP plus EST followed by
LC’ is used in the majority of hospitals worldwide, it should be reserved only for those with
confirmed choledocholithiasis due to its intrinsic invasiveness and is indicated for safer use in
younger patients aged less than 50-60 years.5,6 The main problem with this treatment approach is
that patients may be subjected to unnecessary ERCP first or experience complications such as
ERCP-induced pancreatitis resulting from unintentional pancreatic duct cannulation.28 Patients
who are most at risk for ERCP-related complications (specifically PEP) are those with the lowest
indication for needing that procedure.18 ERCP should be mainly used therapeutically and not for
sole diagnostic purpose given the risk of PEP.21 A couple of reasons that EST may be an
inappropriate treatment choice or difficult to perform depend on stone size, shape, number,
intrahepatic location, or impaction.5
The skilled expertise needed to perform bile duct exploration laparoscopically (LCBDE)
is as not readily available at most facilities compared to availability of endoscopists proficient in
ERCP. Given this resource limitation, it makes sense why pre-op ERCP first plus subsequent LC
is the most clinically used approach despite some of the evidence contradicting its
effectiveness.6,12 An explanation for this is related to its steep learning curve and insufficient
available expertise in advanced laparoscopy in most medical centers, specifically when T-tube
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placement is required because it is a challenging maneuver.1,5,6 LCBDE requires expertise in
using diverse medical instruments including choledochoscope, Dormia basket, dilatation balloon,
intracorporeal laparoscopic suturing, and specific laparoscopic maneuvers. The other issue with
this advanced technique is that this set of instruments are very costly which is not practical for
routine use in most hospitals.1
Consequently, majority of surgeons prefer ERCP or open CBD exploration as compared
to LCBDE because of the advanced technique involved.16 When comparing a survey of the
breakdown of preferences among general surgeons in the U.S. although 44% are capable of
performing LCBDE, only 22% routinely opted to and 75% preferred pre-op ERCP to treat CCL.
Their reasoning for not performing LCBDE was because it is too time consuming (58%), lack of
equipment (24%), lack of skill (1.5%), and higher morbidity (1.5%).5 Few surgeons performing
LC are interested in exploring the extrahepatic bile duct laparoscopically and typically favor
having their patients’ biliary stones removed by a skilled GI endoscopist either before or after
surgery.18 If the laparoscopic procedure to explore the CBD is unsuccessful with transcystic
extraction, then a ramp up approach using other methods is required. When postoperative ERCP
is chosen, often times more than one ERCP is needed which reflects the variation in difficulty of
individual cases and clearance of the ducts by any single technique.25
The reported advantages of one-stage rendezvous technique need to be further
investigated to determine the specific reasons behind its postulated preliminary benefits. One
thought is that data on LERV is inherently biased since it’s only available in large high volume
medical centers conducting trials with this new procedure. Despite the slightly superior results
reported with this novel technique, performing a one-stage process requires a higher degree of
technical skills and synchronization between surgical and endoscopic teams.28
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Almost all of the different techniques discussed can be used if one fails (except in
patients with contraindications) which further contributes to higher success rates to treat CCL.
For example, if pre-op ERCP cannot be completed because of a challenging papillary approach,
then the rendezvous technique could be attempted. Or if during LERV it’s not possible to
laparoscopically insert the cystic duct guide-wire, this one-stage procedure can be completed
instead by an endoscopist with conventional intraoperative ERCP. If a pre-op or intraoperative
ERCP is unsuccessful, treatment can be switched to a LCBDE or open surgical intervention
depending on the availability of a properly trained endoscopist or surgeon.6 Although there is no
gold standard for treating CBD stones presently, whenever a patient presents with acute
complications such as severe cholangitis, ampullary stone impaction, acute biliary pancreatitis
with cholangitis or jaundice, then ERCP plus ES is the best choice to urgently decompress and
drain the bile duct within less than 72 hours.1,5
There is clearly a spectrum of variability of techniques, their outcomes, and associated
complications just as there is variation in how each unique patient will tolerate one or the other.
At the present moment, not a single study exists that compares and contrasts the entire spectrum
of CCL treatments (LC + LERV, LCBDE, ERCP – pre-op/post-op/intraoperative). ERCP timing
is frequently dictated by endoscopist expertise, preferences, and resources rather than actual
superiority of one treatment strategy over another.6,19 The use of ERCP is on the rise and
expected to be utilized increasingly over time in large facilities. Despite a fair amount of data
highlighting the disadvantages of this specialized endoscopic technique (particularly less than
ideal morbidity and mortality rates), it remains the most commonly performed procedure for
patients with stones in the biliary tree. If overreliance and overuse of therapeutic ERCP
continues to occur, there may need to be a shift in treatment protocol where stronger emphasis in
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clinical practice is put on weighing the benefits versus risks to perform this procedure only when
appropriate to avoid complications and improve patient outcomes.
When relying upon systematic reviews of data to form hypotheses and draw conclusions,
the main difficulty in this area of research stems from issues in quality of existing RCTs, the
degree of bias (depending on the author’s point of view as a surgeon or endoscopist), small
sample size, and heterogeneity in the combination of timing of interventions with multi-stage
approaches.24 With so many different professionals and resources varying across medical
centers, the best approach is theoretically one based on all the options available at the same
facility combined with careful clinical judgement of the surgeon or endoscopist. Modification of
each specific strategy should be tailored to each person considering the risks, advantages, and
disadvantages to maximize outcomes and quality of life (see appendix table 5).6 As the trend and
demand for more personalized healthcare continues to escalate, when choosing a one-step or
two-step CCL treatment method, providers should take into account individualized patient risk
factors, operative risk, personal past medical and surgical history, comorbidities, age, and patient
preference.
Conclusion
Gallstone disease is one of the most common and costliest conditions across healthcare
systems throughout the world. In an overwhelming majority of cases, biliary tract disorders are
in some way associated with gallstones and high rates of simultaneous conditions in patients is
reported in the literature. The relationship between gallstone and biliary disease is complex with
numerous nuances and challenges in the work-up and diagnostic process. The management of
CCL has evolved dramatically since the introduction of laparoscopic techniques from an
operative open surgical field to minimally invasive procedures. The information presented in this
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extensive literature review has important implications for future clinical and surgical practice in
both primary care and gastroenterology specialty.
Currently the two-stage approach is most often used in practice but with the promising
data presented on one-stage interventions as potentially more efficient and successful, there
needs to be more studies comparing single-stage techniques head-to-head. There is a lack of
RCTs in the literature analyzing options solely for one-step options.24 In general, rigorous
clinical trials studying many different types of treatment are lacking, but it is somewhat
unrealistic to conduct them in the future. Treatment choice may be influenced by economic
pressure in leaning towards single-stage management.6 More research needs to test the one-stage
versus two-stage approach and its impact on clinical practice as it relates to the time, training,
financial cost, scheduling, and coordination of gastroenterology, surgical, and endoscopy teams
to provide the most efficient and effective services.
The research presented suggests there is evidence that does not support the use of preoperative ERCP and EST plus LC in a multi-stage treatment series. Although the rendezvous
method is not widely adopted and performed due to its novelty, it rivaled ERCP in superb bile
duct clearance rates with the added advantage of fewer ERCP-related complications, cheaper
cost, and shorter hospital duration. LERV is an exciting new approach to managing this niche of
patients with both stones in the gallbladder and bile duct, but not enough research has been done
yet. More studies need to be conducted with a large volume of patient sample size to attempt to
standardize the LERV procedure and validify its hopeful preliminary results.28 Before this type
of research can be conducted, more surgeons and endoscopists in multicenter large healthcare
practices need to be trained to perform this innovative one-step laparoendoscopic technique.
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An important future goal would be for GI endoscopists and surgeons to collaboratively
formulate a diagnostic flow chart and/or management algorithm related to imaging and treatment
protocols to guide the provider while taking into consideration baseline risk stratification. This
type of algorithm should aid in helping to reduce the number of unnecessary ERCPs. Because of
excessive ERCP use in the real world, the strategy of only using ERCP in highly selective cases
should be adopted to reduce number of these invasive endoscopic procedures in patients
undergoing LC.18 Future research should focus on large, multicenter, RCTs assessing long-term
outcomes, real-world implications that may change current practices, cost data, and quality-oflife measures.24 Additionally, more data needs to be collected in order to show cost efficacy for
regular monitoring and surveillance testing for intermediate and high risk CBD stone patient
groups to reduce complications, morbidity, and hospitalizations.
It’s likely that ERCP in addition to LC will remain the mainstay of treatment for patients
with concomitant gallstones and bile duct stones because of its widespread availability of
technical expertise and equipment at large hospitals, but also for its highly successful bile duct
clearance rates. Cholecystectomy procedures are standardly performed for most CCL patients
and its role will continue to be crucial in management with the exclusion of those with higher
operative risks. Although the most effective approach to managing CCL is controversial, the one
thing that is agreed upon in the literature is that the best management choice is determined at the
specific clinical practice level led by local professional expertise, preferences, and resources
instead of true superiority of one strategy over another. The most appropriate treatment method
will also vary based on a combination of patient demographics and risk stratification.6,26
Definitive conclusions regarding the most effective CCL management are unable to be
drawn, due to the various mixed results reporting positive, negative, or equal outcomes between
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interventions, and also because of lack of studies reporting the long-term outcomes of recurrent
choledocholithiasis and quality of life assessments.24 Because there are various definitions used
and outcomes measured among differing authors when analyzing various CCL treatment
procedures, it’s likely to play a role in the mixed results reported. There are many variables that
cannot always be controlled for, particularly patient demographics, or how certain people tolerate
one procedure but not another, or develop complications while others never do. The shortage of
studies spanning over a long period of time stems from the difficulty of continuous follow up of
patient years after an intervention and quality of life measures can be tough to define. Although
most studies listed no conflicts of interest and made attempts to eliminate bias, many of the
authors were surgeons or GI endoscopists which may have swayed their preference for certain
procedures and favorable outcomes to support their views. Despite conflicting evidence, the
hypothesized gold standard treatment should include expert opinion by multiple different
professionals (multidisciplinary team) including gastroenterologists, surgeons, endoscopists,
anesthesiologists, and radiologists.
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